Compugen Ltd. is a clinical-stage predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange, and its market cap is about $367.4M as of May 2023. Compugen was established as a computational drug discovery service provider in 1993 and has since evolved into a leader in the field of immuno-oncology.

Compugen's vision is to use its predictive computational platform to discover untapped drug targets and extend the reach of cancer immunotherapies to new patient populations. Compugen's platform leverages the power of artificial intelligence and big data to identify novel drug candidates that modulate the immune system and enhance anti-tumor responses.

Compugen's pipeline consists of several potentially first-in-class therapeutic antibodies targeting novel pathways that are currently being evaluated in multiple clinical trials. One of Compugen's most advanced programs is COM701, a monoclonal antibody that blocks PVRIG, a novel immune checkpoint that Compugen discovered and validated. COM701 is being tested as a monotherapy and in combination with other immune checkpoints in patients with advanced solid tumors.

Compugen has also received several awards and recognitions for its innovation and excellence in the field of drug discovery. In 2020, Compugen was named one of the world's most innovative companies by Fast Company magazine. In 2019, Compugen received the prestigious SCRIP Award for Best Licensing Deal for its collaboration with AstraZeneca. In 2018, Compugen was selected as one of the Fierce 15 biotech companies by FierceBiotech.

Foundation: 1993

Headquarters: Holon, Israel

Website: https://www.cgen.com/

Solegreen Ltd is a leading company in the field of renewable energy in Israel. The company was founded in 2007 by a group of entrepreneurs who shared a vision of creating a greener and cleaner future for the country and the world. The company's headquarters are located in Tel Aviv, and its market cap is about $238.8M as of May 2023.

Solegreen's main activity is developing and operating solar power plants, both on rooftops and on open land. The company has installed over 500 MW of solar capacity across Israel and has plans to expand to other markets in the Middle East and Africa. The company also provides energy efficiency solutions and smart grid services to its customers, helping them reduce their carbon footprint and save on electricity costs.

Solegreen has received several awards and recognitions for its achievements and innovations in the renewable energy sector. In 2019, the company won the Eilat-Eilot Renewable Energy Innovation Award for its Ashalim project. In 2020, the company was ranked among the top 10 solar developers in the world by PV Magazine. In 2021, the company was selected as one of the finalists for the Zayed Sustainability Prize, a prestigious global award that honors outstanding contributions to sustainable development.

Solegreen's vision is to become a global leader in renewable energy and to make a positive impact on the environment and society. The company believes that solar power is not only a viable alternative to fossil fuels, but also a catalyst for social and economic development. By providing clean and affordable energy to millions of people, Solegreen hopes to create a brighter future for everyone.

Foundation: 2007
Headquarters: Tel Aviv, Israel
Website: https://solegreen-group.com

Gamida Cell Ltd. is an advanced cell therapy company based in Israel that is committed to finding cures for patients with cancer and other serious diseases. The company was founded in 1998 by Dr. Tony Peled and Dr. Reuven Or, who developed a novel technology platform called NAM (Nicotinamide) that enhances the functionality and potency of cell therapies.

The company's headquarters are located in Jerusalem, and it has a manufacturing facility in Kiryat Gat. The company is publicly traded on the Nasdaq under the ticker symbol GMDA and has a market cap of about $116.3 million as of May 2023.

The company's vision is to create a pipeline of NAM-enabled cell therapies that can deliver a curative approach for patients with cancer and other diseases that are not adequately addressed by existing treatments. The company's lead product candidate is omidubicel-onlv, an allogeneic cell therapy for patients with hematologic malignancies who need a bone marrow transplant. Omidubicel-onlv received FDA approval in April 2023, making it the first NAM-enabled cell therapy to reach the market.

The company is also developing GDA-201, a natural killer (NK) cell therapy for patients with solid tumors and lymphomas. GDA-201 is currently in phase 1/2 clinical trials and has shown promising results in terms of safety and efficacy. The company has received several awards and recognitions for its innovative research and development, such as the Frost & Sullivan Technology Innovation Award, the Israel Innovation Authority Grant, and the BioWorld MedTech Breakthrough Award.

Foundation: 1998

Headquarters: Jerusalem, Israel

Website: https://www.gamida-cell.com/

Sol-Gel Technologies Ltd. is a dermatology company based in Israel that develops innovative topical skin medications. The company was founded in 1997 by Dr. Alon Seri-Levy and Prof. David Avnir, who pioneered the use of sol-gel technology for drug delivery. Sol-Gel's headquarters are located in Nes Ziona, a city in central Israel. As of May 2023, the company has a market cap of $108.7M.

Sol-Gel's vision is to improve the lives of patients with skin diseases by providing them with effective and safe treatments that are based on its proprietary sol-gel technology. Sol-gel technology allows the encapsulation of active ingredients in silica-based microcapsules, which can enhance their stability, bioavailability, and penetration into the skin.

Sol-Gel has two FDA-approved products that are marketed by Galderma in the US since 2022: Twyneo® and Epsolay®. Twyneo® is a combination of benzoyl peroxide and tretinoin for the treatment of acne vulgaris, and Epsolay® is a microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea. Both products have demonstrated superior efficacy and safety compared to their respective monotherapies in clinical trials.

In 2021, Sol-Gel received the Frost & Sullivan Technology Innovation Leadership Award for its achievements in the dermatology market. The award recognizes Sol-Gel's excellence in innovation, customer value, and market impact.

Foundation: 1997
Headquarters: Nes Ziona, Israel
Website: https://www.sol-gel.com/

CollPlant Biotechnologies Ltd. is a biotechnology company based in Israel that specializes in developing regenerative medicine solutions using plant-derived recombinant human collagen (rhCollagen). The company was founded in 2004 and has its headquarters in Rehovot, Israel. As of May 2021, the company had a market cap of about $94.6 million.

The vision of CollPlant is to create a new standard of care for tissue repair and organ manufacturing using its proprietary rhCollagen technology. The company has developed several products and platforms based on its rhCollagen, such as BioInks for 3D bioprinting of tissues and organs, dermal fillers for aesthetic medicine, and wound healing products for chronic and acute wounds.

One of the most notable projects of CollPlant is its collaboration with United Therapeutics Corporation to develop 3D bioprinted lungs for transplantation. In 2018, the companies signed a licensing and development agreement that granted United Therapeutics exclusive rights to use CollPlant's BioInks for lung manufacturing. In 2020, the companies announced the expansion of their partnership to include up to three additional organs.

In recognition of its innovation and leadership in the field of regenerative medicine, CollPlant received the Frost & Sullivan 2020 Technology Innovation Leadership Award for its BioInks. The award highlights the company's ability to address the unmet needs of the tissue engineering and organ manufacturing markets with its novel and versatile rhCollagen technology.

Foundation: 2004

Headquarters: Rehovot, Israel

Website: https://www.collplant.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company based in Israel that develops and produces recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx®. The company was founded in 1993 by Dr. Yoseph Shaaltiel and has a manufacturing facility in Carmiel, in Western Galilee.

Protalix's vision is to become a fully integrated biopharmaceutical company that leverages the advantages of its unique technology platform and internal research and development capabilities. The company's pipeline consists of proprietary versions of recombinant proteins that target established pharmaceutical markets and have clinically improved profiles.

One of the company's products is Elelyso®, a treatment for Fabry disease, which was approved by the FDA in 2012 and by other regulatory authorities around the world. Protalix has also collaborated with Chiesi Global Rare Diseases to develop pegunigalsidase alfa, another treatment for Fabry disease, which received a positive opinion from the CHMP in February 2023.

Protalix BioTherapeutics, Inc. has a market cap of $92.5M as of May 2023. The company is listed on the NYSE American and the Tel Aviv Stock Exchange under the ticker symbol PLX. Protalix is committed to delivering innovative therapies and solutions for people affected by rare diseases and other unmet medical needs.

Foundation: 1993
Headquarters: Karmiel, Israel
Website: https://protalix.com/

Enlivex Therapeutics Ltd. is a clinical-stage company that develops innovative immunotherapies based on macrophage reprogramming. Macrophages are immune cells that can either promote or suppress inflammation and tissue repair, depending on their state. Enlivex aims to restore the balance of macrophages in diseases where they are out of sync, such as sepsis, COVID-19, and solid cancers.

The company was founded in 2005 as a spin-off from the Hebrew University of Jerusalem and is headquartered in Nes-Ziona, Israel. It is listed on Nasdaq under the ticker symbol ENLV and has a market cap of about $92.8 million as of May 2023.

Enlivex's vision is to establish new equilibriums that solve complex diseases by harnessing the power of macrophages. Its lead product candidate, Allocetra™, is a cell-based therapy that reprograms macrophages from a pro-inflammatory to an anti-inflammatory state, thereby enhancing their ability to resolve inflammation and promote tissue healing.

Allocetra™ is currently being tested in several clinical trials for different indications, including organ failure associated with sepsis, advanced-stage solid tumors with peritoneal metastases, and COVID-19. The company has received orphan drug designation from the FDA and the EU for sepsis and peritoneal carcinomatosis, as well as a special life-threatening regulation from the EU that could enable post-phase II marketing approval for sepsis.

Foundation: 2005

Headquarters: Nes Ziona, Israel

Website: https://www.enlivex.com/

MediWound Ltd is a biotechnology company based in Israel that specializes in developing innovative treatments for severe burns and chronic wounds. The company was founded in 2001 by Dr. Lior Rosenberg, a leading plastic surgeon and burn specialist, who recognized the need for better solutions for wound care. MediWound's headquarters are located in Yavne, Israel, and its shares are traded on the Nasdaq Stock Market under the symbol MDWD. As of May 10, 2023, the company had a market cap of $79.0 million.

MediWound's vision is to improve the quality of life of patients suffering from severe and hard-to-heal wounds and to reduce the burden on the healthcare system. The company's flagship product, NexoBrid, is a topical gel that removes dead tissue from burn wounds without harming healthy tissue. NexoBrid has been approved by the European Medicines Agency (EMA) and the Israeli Ministry of Health and is currently undergoing a phase 3 clinical trial in the United States. NexoBrid has been used to treat over 7,000 patients in more than 40 countries and has demonstrated superior clinical outcomes compared to the standard of care.

In addition to its product pipeline, MediWound has received several awards and recognitions for its achievements and innovations. In 2019, the company won the Frost & Sullivan European Technology Innovation Award for its enzyme-based wound care products. In 2020, the company was selected as one of the Red Herring Top 100 Europe companies and was ranked among the top 10 Israeli biotech companies by Globes. In 2021, the company received the Galien Foundation Prix Galien Israel Award for NexoBrid.

Foundation: 2001
Headquarters: Yavne, Israel
Website: https://www.mediwound.com/

Bonus BioGroup Ltd is a biotechnology company based in Israel that specializes in tissue engineering and regenerative medicine. The company was founded in 2008 and is headquartered in Haifa, Israel. The company's market cap as of May 2023 is about $74.5M.

The company's vision is to develop innovative solutions for tissue regeneration and repair, using its proprietary technology of culturing human cells and tissues in bioreactors. The company's flagship project is the development of a bone graft product that can be used to treat various bone defects and fractures. The product is made from the patient's own fat cells, which are harvested, processed and cultured into bone tissue in the company's bioreactors. The bone tissue is then implanted into the patient's body, where it integrates with the existing bone and restores its function.

The company has received several awards and recognitions for its groundbreaking work in tissue engineering, such as the Frost & Sullivan Technology Innovation Award in 2016, the Israel Innovation Authority Grant in 2017, and the European Commission Horizon 2020 Grant in 2019. The company is also collaborating with leading academic and medical institutions in Israel and abroad, such as the Technion-Israel Institute of Technology, the Rambam Medical Center, and the Mayo Clinic.

Foundation: 2008

Headquarters: Haifa, Israel

Website: https://www.bonusbiogroup.com/

BioLineRx Ltd. is a drug development company that focuses on oncology. It was founded in 2003 and is headquartered in Modi'in, Israel. Its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. As of May 2023, its market cap is $46.9M.

BioLineRx's vision is to transform science into medicine by developing novel compounds that will deliver life-changing innovations for patients. It has a pipeline of powerful technologies that target different aspects of cancer, such as stem cell mobilization, immune cell infiltration, and patient-specific neoantigens.

One of its leading projects is **Motixafortide (BL-8040)**, a drug that blocks the interaction between CXCL12 and CXCR4, leading to robust mobilization of stem cells to the peripheral blood for collection and transplant, as well as increased immune cell infiltration into tumors and reduced immunosuppression in the tumor microenvironment. Motixafortide is currently in phase 3 clinical trials for stem cell mobilization and in phase 2 clinical trials for solid tumors.

BioLineRx has received several awards for its innovation and excellence, such as the Frost & Sullivan 2019 European Technology Innovation Award for AGI-134 and the Deloitte Israel Technology Fast 50 Award for being one of the fastest-growing technology companies in Israel.

Foundation: 2003
Headquarters: Modi'in, Israel
Website: https://www.biolinerx.com/